Important Resolutions of AGM 2017

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU
June 11, 2017
Clarification on the news article by Commercial Times
June 29, 2017
  1. Date of the meeting: June 28, 2017
  2. Resolution #1: The 2016 earning distribution and expense appropriation was recognized.
  3. Resolution #2: Amended items—None
  4. Resolution #3: The 2016 Annual report and financial report was recognized.
  5. Resolution #4: Election of Board Directors and Supervisors—None
  6. Resolution #5: Others—Passed the amendment of “Procedure of asset acquisition and disposal.”
  7. Any other matters that need to be specified: None.